ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Exposome-wide association study and predictive risk score for incident Alzheimer's disease and related dementias.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionEnvironmental exposures contribute substantially to Alzheimer's disease and related dementias (ADRD), yet comprehensive exposome-wide investigations systematically evaluating multi-domain environmental factors remain limited and lacking utility for precision medicine.
methodsWe conducted an exposome-wide association study (ExWAS) among 499,992 UK Biobank participants, examining 193 exposures across five domains (social, physical, chemical, lifestyle, and ecosystems). Cox proportional hazard models with Bonferroni correction identified ADRD-associated exposures. We used the XGBoost classifier to build a predictive model and further developed an exposomic risk score (ERS) for risk stratification.
resultsDuring a 15.3-year median follow-up, 8881 participants (1.77%) developed ADRD, including 4000 with Alzheimer's disease. ExWAS identified 76 exposures after Bonferroni correction. The prediction model achieved area under the curve (AUC) = 0.718, outperforming demographics+apolipoprotein E (APOE) status alone (AUC = 0.678). The ERS stratified ADRD risk (highest vs lowest quartile hazard ratio [HR] = 2.97, 95% confidence interval [CI]: 2.59-3.41). DISCUSSION: The ERS has the potential to contribute to clinically relevant prevention strategies for ADRD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.